Previous studies using post-mortem human brain extracts demonstrated that PrP in Creutzfeldt-Jakob disease (CJD) brains is cleaved by a cellular protease to generate a C-terminal fragment, referred to as C2, which has the same molecular weight as PrP-(27-30), the protease-resistant core of PrP Sc (1). The role of this endoproteolytic cleavage of PrP in prion pathogenesis and the identity of the cellular protease responsible for production of the C2 cleavage product has not been explored. To address these issues we have taken a combination of pharmacological and genetic approaches using persistently infected scrapie mouse brain (SMB) cells. We confirm that production of C2 is the predominant cleavage event of PrP Sc in the brains of scrapieinfected mice and that SMB cells faithfully recapitulate the diverse intracellular proteolytic processing events of PrP Sc and PrP C observed in vivo. While increases in intracellular calcium (Ca 2؉ ) levels in prion-infected cell cultures stimulate the production of the PrP Sc cleavage product, pharmacological inhibitors of calpains and overexpression of the endogenous calpain inhibitor, calpastatin, prevent the production of C2. In contrast, inhibitors of lysosomal proteases, caspases, and the proteasome have no effect on C2 production in SMB cells. Calpain inhibition also prevents the accumulation of PrP Sc in SMB and persistently infected ScN2A cells, whereas bioassay of inhibitor-treated cell cultures demonstrates that calpain inhibition results in reduced prion titers compared with control-treated cultures assessed in parallel. Our observations suggest that calpain-mediated endoproteolytic cleavage of PrP Sc may be an important event in prion propagation.
1 scrapie in sheep, chronic wasting disease (CWD) of deer and elk, and human Creutzfeldt Jakob disease (CJD). While the detailed mechanism of prion propagation remains to be determined, considerable evidence argues that prions are devoid of nucleic acid and are composed largely, if not entirely, of the scrapie isoform of the prion protein (PrP), referred to as PrP Sc . During the disease process, PrP Sc acts as a template for conversion by imposing its conformation on the normally benign host-encoded version of the prion protein referred to as PrP C (reviewed in Ref. 2) . The conversion of PrP C into PrP Sc involves a profound conformational change: PrP C has a high ␣-helical content and is virtually devoid of ␤-sheet while PrP Sc has high ␤-sheet content (3) (4) (5) . A hallmark of PrP Sc is its insolubility in non-denaturing detergents and its relative resistance to protease digestion in vitro. Proteinase K (PK) treatment of PrP Sc results in the persistence of a core molecule, referred to as PrP- (27) (28) (29) (30) , consisting predominantly of amino acid residues 89 -230 (mouse PrP residue numbering) (6) . In contrast to PrP Sc , PrP C is soluble in detergents and sensitive to proteolytic digestion by PK.
In addition to these biochemical differences, PrP C and PrP Sc are subject to diverse intracellular proteolytic processing events (7) (8) (9) . Previous studies demonstrated that human PrP C undergoes proteolytic cleavage at amino acids 110/111 within a segment of conserved hydrophobic amino acids to produce an ϳ17-kDa C-terminal fragment referred to as C1, while a PKresistant fragment of PrP is produced in infected brains, apparently as a result of cleavage at the same location that PK cleaves PrP Sc in vitro (following amino acid residue 88 in mouse PrP). The latter cleavage produces a C-terminal fragment, referred to as C2, with the same apparent molecular mass as unglycosylated PrP- (27) (28) (29) (30) (1) . While recent studies suggest that ADAM/TACE (A disintegrin and metalloprotease/tumor necrosis factor ␣-converting enzyme) matrix metalloproteases may be responsible for the generation of the C1 fragment (10) , the identity of the cellular protease responsible for endoproteolytic cleavage of PrP Sc and the role of the C2 cleavage product in prion pathogenesis have not been explored. In these studies we have employed a combination of pharmacological and genetic approaches to address these issues. Our studies indicate that endoproteolytic cleavage of PrP Sc is facilitated by calpains. The calpain family of proteolytic enzymes is comprised of ubiquitous and tissue-specific isoforms of Ca 2ϩ -activated cysteine proteases that modify the properties of substrate proteins by cleavage at a limited number of specific sites (11) generating large, often catalytically active fragments. The regulatory function of calpains is in contrast to the digestive functions of, for instance, the lysosomal proteases or the proteasome. Proteolysis by calpains features in a wide range of cellular functions including, cellular differentiation, integrin-mediated cell migration, cytoskeletal remodeling, and apoptosis (reviewed in Ref. 12 ). Calpains have also been implicated in a number of neurodegenerative diseases including brain injury, Alzheimer's disease, Parkinson's disease, and Huntington's disease (11, 13, 14) . Calpain activity is tightly regulated in vivo by Ca 2ϩ and by the specific intracellular protein inhibitor calpastatin. The two ubiquitously expressed calpains are m-calpain and -calpain, which are heterodimers made up of a catalytic (ϳ80 kDa) and a common regulatory (ϳ30 kDa) subunit that require millimolar and micromolar Ca 2ϩ concentrations, respectively, for activation. Transgenic mice in which the gene for the calpain regulatory subunit was ablated lacked detectable m-and -calpain activity and die at midgestation (15) .
Previous studies have identified several distinct classes of prion inhibitors including substituted tricyclic derivatives, tetrapyrrole compounds, cysteine protease inhibitors, branched polyamines, and specific anti-PrP antibodies (reviewed in Ref. 16) . While the mode of action of blocking antibodies appears to involve prevention of PrP Sc formation by binding to PrP C and branched polyamines bind to and denature PrP Sc in acidic compartments, the mechanism of inhibition by other inhibitors of PrP Sc formation is unknown. Our studies suggest that calpaindependent endoproteolytic cleavage of PrP Sc may be an important step in PrP Sc formation and prion propagation.
EXPERIMENTAL PROCEDURES
Chemicals and Antibodies-All immunoblots probed with Fab D-18 were developed using horseradish peroxidase-conjugated goat anti-Hu secondary antibody and ECL or ECL-Plus detection (Amersham Biosciences) and exposed to x-ray film. Anti-calpastatin and anti-actin antibodies were purchased from Chemicon International, Inc., Temecula, CA. All protease inhibitors were purchased from Calbiochem, EMD Biosciences, Inc., San Diego, CA. Ionomycin and A23187 were purchased from Sigma-Aldrich.
Cell Culture and Pharmacologic Treatments-Scrapie-infected mouse brain (SMB) cells (17) , SMB-PS cells cleared of infectivity by pentosan sulfate (PS) treatment (18) , neuro2A neuroblastoma cells (N2A) (obtained from the American Type Culture Collection, Manassas, VA), and ScN2A, which are a highly susceptible subline of N2A cells persistently infected with mouse-adapted scrapie RML prions (19) , were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, penicillin (100 units/ml) and streptomycin (100 mg/ml) (Invitrogen) at 37°C in 5% CO 2 . SMB and SMB-PS cells were routinely subcultured (1:6) every 4 days, and ScN2A cells were split 1:10 using 0.05% (w/v) trypsin-EDTA (Invitrogen). For inhibitor studies 0.75 ϫ 10 6 SMB cells were seeded on 6-cm dishes, and 1.6 ϫ 10 6 SMB cells were seeded on 10-cm dishes. Stock solutions of protease inhibitors in dimethyl sulfoxide (Me 2 SO) were added to cell culture media at various final concentrations. During inhibitor treatments, medium containing fresh inhibitor was replaced daily, and controltreated cells were cultured in medium containing an equal volume of Me 2 SO without inhibitor. When cells achieved confluence, usually after 4 days, cells were lysed, and total protein content was determined. For Ca 2ϩ ionophore treatments, the culture medium of subconfluent monolayers of SMB cells was replaced for 1 h with Optimem (Invitrogen) containing 2 mM CaCl 2 and various concentrations of ionomycin or A23187, after which detergent extracts were prepared. In transfection experiments SMB cells were transfected at 90% confluence with 10 g of a modified version of the pRK5 expression plasmid containing a selectable neomycin resistance marker and the full-length human calpastatin cDNA using LipofectAMINE 2000 (Invitrogen). Control cultures were transfected with empty vector expressing only the neomycin resistance gene. Transfected cultures were bulk-selected in the presence of 0.35 mg/ml G418.
Analysis of PrP-Brain homogenates (10% (w/v) in phosphate-buffered saline (PBS)) from RML scrapie-infected CD-1 Swiss mice and uninoculated CD-1 Swiss mice were prepared by repeated extrusion through an 18-gauge syringe needle followed by a 21-gauge needle in PBS lacking calcium and magnesium ions. Nuclei and debris were removed from brain homogenates by brief centrifugation at 1,000 ϫ g. Sarkosyl was added at a final concentration of 2%. For cell cultures, after washing in PBS, cells were treated with cold lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 0.5% sodium deoxycholate, 0.5% Igepal CA-630), and cell debris was removed by centrifugation at 3,000 ϫ g for 5 min. Total protein content of cell culture or brain extracts was determined by bicinchoninic acid (BCA) assay (Pierce Biotechnology, Inc.) using a BioTek plate reader. For deglycosylation, 50-g protein aliquots were mixed with recombinant peptide:N-glycosidase F (PNGase F) for 1 h at 37°C, as specified by the supplier (New England Biolabs, Beverly, MA). In all experiments involving PK digestion, the final concentration of PK was 20 g/ml, and the ratio of total protein to PK was 50:1. Samples were incubated for 1 h at 37°C, and digestion was terminated by the addition of phenylmethylsulfonyl fluoride to a final concentration of 2 mM. For PrP- (27) (28) (29) (30) analysis in brain extracts, homogenates containing 50 g of total protein were treated with PK. For PrP- (27) (28) (29) (30) analysis in cultured cells, detergent extracts containing 1 mg of total protein in the case of SMB cells or 2 mg of total protein in the case of ScN2A cells were PK-treated, and insoluble PrP-(27-30) was purified by ultracentrifugation for 1 h at 100,000 ϫ g in a Beckman TLX100 ultracentrifuge. Samples were boiled in an equal volume of 2ϫ nonreducing SDS loading buffer for 5 min and resolved by SDS-PAGE. Proteins were transferred to polyvinylidene fluoride membranes and blocked with 5% (w/v) nonfat milk in Tris-buffered saline containing Tween 20.
Cell Viability-0.2 ϫ 10 6 SMB cells were seeded in 6-well plates in medium containing 50 M MDL28170, calpeptin, or calpain inhibitor IV. Medium containing fresh inhibitor was changed daily, and controltreated cells were cultured in medium containing an equal volume of Me 2 SO without inhibitor. When cells achieved confluence they were trypsinized and reseeded onto 6-well plates, and the following day inhibitor-containing medium was replaced with normal medium containing 1 g/ml calcein-AM and propidium iodide dyes for 30 min at 37°C. Medium was removed, and cells were washed briefly with PBS. Cells were observed under ϫ10 magnification using an Olympus IX 50 inverted fluorescent microscope. Counts of live cells fluorescing green and dead cells fluorescing orange were determined in a total of 4 fields for each well with a minimum of 200 cells counted in each field. Analysis was performed in triplicate for each inhibitor, and the average and standard deviations were calculated for each condition.
Bioassay-The RML mouse scrapie prion isolate from Swiss mice was passaged in Swiss CD-1 mice obtained from Charles River Laboratories (Wilmington, MA). For inoculation of Swiss CD-1 mice, 10% (w/v) homogenates of RML-infected mouse brain were prepared by repeated extrusion through an 18-gauge syringe needle followed by a 21-gauge needle in PBS lacking calcium and magnesium ions. Samples were diluted 10-fold in PBS prior to inoculation. Mice were anesthetized with a mixture of halothane and O 2 , and inoculated intracerebrally with 30-l samples prepared from brain using a 27-gauge needle inserted into the right parietal lobe. All mice were thereafter examined three times weekly for clinical signs of prion disease. As soon as any animal was identified as having progressive neurological symptoms consistent with prion infection, the animal was humanely killed by asphyxiation with CO 2 . For bioassay of prion infectivity in MDL28170-treated and non-treated SMB cells, groups of CD-1 Swiss mice (n ϭ 12) were inoculated intracerebrally with MDL28170-treated and control-treated SMB cells passaged in parallel. Cells were suspended in 1 ml of PBS, and a 30-l cell suspension (ϳ1.8 ϫ 10 4 cells) was inoculated in each case into the right parietal lobe using a 27-gauge needle. The end point of the bioassay was the time to appearance of definitive clinical symptoms, referred to as the scrapie incubation time.
Quantification of PrP and Statistical Analyses-Densitometric analysis of C1, C2, and PrP-(27-30) levels in SMB cells was performed with a Kodak Imaging System using Image for Windows version 3b (Scion). All statistical analyses including the Student's t tests were performed using GraphPad Prism version 4.0 for Windows, GraphPad Software, San Diego CA.
RESULTS

PrP C and PrP Sc Are Cleaved by Endogenous Proteases in Brain and Cultured Cells to Produce Cleavage Products with Distinct Biochemical Properties-While PrP
Sc is usually defined by its relative resistance to protease digestion in vitro, we avoided the use of PK in our analyses to allow the detection of intact and endogenously cleaved forms of PrP C and PrP Sc . Since the C1 and C2 cleavage products contain the sites for asparagine (Asn)-linked glycosylation of PrP ( Fig. 1 ) and, like full-length PrP, consist of multiple glycoforms that are normally obscured by other glycosylated and unglycosylated PrP species, we removed Asn-linked glycans by treatment of mouse brain homogenates and cultured cell extracts with PNGase F to simplify our analysis of PrP C and PrP Sc processing. For immunologic detection of mouse PrP we used recombinant PrP-spe-cific Fab D-18, which detects an epitope between amino acid residues 133 and 157 (20) and therefore recognizes full-length PrP C , PrP Sc , C2, and C1 ( Fig. 1 ). In addition to full-length PrP (F) with an apparent molecular mass of ϳ28 kDa, C-terminal PrP fragments of ϳ21 and ϳ17 kDa were detected in the brains of clinically affected mice infected with mouse-adapted RML scrapie prions (Fig. 2a , lane 7) whereas full-length PrP and the 17-kDa fragment predominated in uninfected mouse brains (Fig. 2a, lane 3) . Like PrP Sc , the 21-kDa fragment was partially resistant to PK and had the same apparent molecular mass as the unglycosylated form of as PrP- (27) (28) (29) (30) (Fig. 2a, lanes 6 and 8) . The 21-kDa fragment therefore corresponds mainly to the PrP Sc -specific cleavage product, designated C2, detected in post-mortem brain extracts from patients with CJD (1, 21) . C2 was also detected in glycosidase-treated brain extracts from Syrian hamsters infected with the Sc237 strain of prions. 2 The ϳ17-kDa PK-sensitive C-terminal PrP fragment, present in uninfected and RMLinfected mouse brain extracts (Fig. 2a) , corresponds to the PrP C -specific cleavage product C1 fragment previously identified in human brain extracts (1). While C2 was predominantly produced under conditions of prion infection, a cleavage product of similar molecular mass as C2, which did not survive treatment with PK, was produced at much lower levels in uninfected mouse brains (Fig. 2a, lane 3) . A similar endoproteolytically cleaved fragment of human PrP, referred to as soluble PrP-(27-30), was detected in previous studies following partial deglycosylation of human platelet material (22) .
Analysis of PrP processing in cultured SMB cells (17) , which are persistently infected with scrapie mouse prions, and their uninfected counterparts SMB-PS cells, which were cleared of infectivity by chronic pentosan sulfate treatment (18) , revealed that proteolytic processing of PrP C and PrP Sc mirrored the processing of PrP C and PrP Sc observed in vivo, with C2 produced under conditions of prion infection (Fig. 2b) . As expected from previous studies of chronically infected cells, levels of PrP-(27-30) were roughly 10-fold lower in chronically infected cultured cells compared with brain extracts from clinically sick mice.
We took two approaches to ensure that the PrP proteolysis we observed occurred as a result of specific cellular proteases and not as a result of nonspecific proteases acting during extraction. First, treatment of 1.25 g of recombinant MoPrP with glycosidase in the presence or absence of 50 g of total protein from Prnp 0/0 brain extract did not result in the appearance of cleavage products similar to C1 and C2. Control samples consisted of untreated recombinant mouse PrP and PNGaseF-treated SMB cell lysate (Fig. 2c) . Second, we observed the same pattern of full-length, C2, and C1 when SMB detergent extracts were prepared in the presence of 0.1 mM phenylmethylsulfonyl fluoride and protease inhibitor mixture (Roche Diagnostics), 0.2 mM MDL28170 or 0.2 mM calpain inhibitor IV compared with control SMB detergent extracts prepared in the absence of inhibitors (Fig. 2d) .
Differential Regulation of C1 and C2 Cleavage in the Infected and Uninfected States-Comparison of C1 and C2 levels in SMB and SMB-PS cells suggested a reciprocal relationship between the two cleavage products in the prion-infected and uninfected states (Fig. 2b, lanes 3 and 7) . In cured SMB-PS cells where C2 is not produced, C1 levels were 4.7 Ϯ 1.6-fold higher (Ϯ S.E., n ϭ 3 independent experiments) than in prioninfected SMB cells. To more fully characterize the relationship between C1 and C2 during prion infection, we analyzed the kinetics of C1 and C2 production in brains of mice inoculated with mouse-adapted RML scrapie prions. While C2 levels increased between 70 and 84 days postinoculation (Fig. 3a) , the presence of cleavage products presumably corresponding to the PK-sensitive 21-kDa fragment present at low levels in uninfected mouse brain (Fig. 2a, lane 3) made the exact time of increased C2 production hard to determine. Nonetheless, as C2 levels continued to increase during prion infection, C1 levels correspondingly decreased at the end stage of disease by ϳ3-2 K. Nishina and S. Supattapone, personal communication. , and C1 and C2 is also shown as well as the expected molecular weights of the C1 and C2 fragments. and 4-fold at 126 and 140 days, respectively. PrP- (27) (28) (29) (30) was first detected at 56 days ( Fig. 3b) with substantial amounts appearing by 84 days. Resolving the various PrP-(27-30) glycoforms into a single PK-resistant, deglycosylated 21-kDa product resulted in PrP Sc detection in brain extracts as early as 42-days postinoculation (Fig. 3c) .
Treatment of Prion-infected Cells with Cellular Protease Inhibitors Indicates That Production of C2 Is Mediated by Cal-
pains-To identify the cellular protease that generates C2, we tested a panel of membrane permeable inhibitors for their ability to affect C2 production in SMB cells. Cells were treated with 20 M cathepsin inhibitor III (Z-FG-NHO-BzOME), a cysteine protease inhibitor that selectively inhibits cathepsin B, cathepsin L, cathepsin S, and papain; 2 M cathepsin L inhibitor III (Z-FY(t-Bu)-DMK) an irreversible inhibitor of cathepsin L; 20 M caspase inhibitor III (Boc-D-FMK), a cell-permeable, irreversible, broad spectrum caspase inhibitor; 2 M caspase 3 inhibitor III (Ac-DEVD-CMK) a potent and irreversible inhibitor of caspase-3 as well as caspase-6, caspase-7, caspase-8, and caspase-10; 1 M of the proteasome inhibitor MG132 (carbobenzoxyl-L-leucinyl-L-leucinyl-L-leucinal-H); 5 M lactacystin, a highly specific irreversible proteasome inhibitor; 50 M of the calpain inhibitor MDL28170 (carbobenzoxy-valinyl-phenylalaninal); 50 M of the calpain inhibitor calpeptin (benzyloxycarbonylleucyl-norleucinal); and, 50 M of calpain inhibitor IV (Z-LLY-FMK) a potent, cell-permeable, and irreversible calpain inhibitor. Only calpain inhibitors MDL28170, calpeptin, and calpain inhibitor IV inhibited production of C2 while inhibitors of lysosomal proteases, caspases, and the proteasome had no effect (Fig. 4, a and b) . The irreversible calpain inhibitor IV was most effective resulting in apparently complete elimination of C2, whereas treatment with MDL28170 and calpeptin produced significant reductions in C2, averaging 63 Ϯ 19.7% (ϮS.D., n ϭ 3 independent experiments, p ϭ 0.031) and 71 Ϯ 7.1% (ϮS.D., n ϭ 3 independent experiments, p ϭ 0.0033), respectively (Fig. 4b) . Since proteolysis by calpains features in a wide range of cellular functions, to ensure that SMB cells could tolerate the maximal concentrations of calpain inhibitors used in these experiments (50 M) we monitored cell viability (Fig. 4c ) and found no difference in cell survival between the inhibitor-treated and control-treated cultures, suggesting that reduced C2 production was not the result of a nonspecific effect of calpain inhibitors on cell toxicity.
To more fully investigate the effect of calpain inhibitors on PrP processing, SMB cells were cultured in the presence of various concentrations of calpain inhibitor IV or MDL28170. In the case of calpain inhibitor IV treatments, cells were lysed after 4 days when confluent; in the case of MDL28170 treatments, cells were lysed after 4 days when confluent (passage 1) and subcultured for a second passage in the presence of the same concentration of MDL28170. Levels of C2 in calpain inhibitor IV-treated SMB cells were reduced in a dose-dependent manner (Fig. 5, a and b) . The concentration of calpain inhibitor IV producing 50% inhibition of C2 accumulation (IC 50 ) was calculated to be 0.45 M. As C2 levels decreased in response to calpain inhibition, C1 correspondingly increased reaching levels ϳ2-fold higher than control-treated SMB cells at concentrations between 1 and 25 M. At the highest calpain inhibitor IV concentration, C1 levels declined suggesting partial, nonspecific inhibition of the protease that cleaves PrP C to produce C1. Production of C2 in MDL28170-treated SMB cells was reduced in a time and dose-dependent manner (Fig. 5, c and d) . Treatment for 4 days in the presence of 50 M MDL28170 resulted in a 75 Ϯ 6.8% (Ϯ S.D., n ϭ 3 independent experiments) reduction in C2, whereas after 8 days of treatment C2 was undetectable by immunoblotting. The IC 50 of MDL28170 was estimated to be 4 M. Again, as C2 levels decreased in response to MDL28170 at concentrations between 5 and 50 M, C1 levels correspondingly increased to levels similar to calpain inhibitor IV-treated SMB cells (Fig. 5d) .
Effects of Calpastatin and Calcium Ionophores on C2 Production-Since calpain activity is tightly regulated in vivo by the intracellular protein inhibitor calpastatin, we exploited the unique inhibitory specificity of calpastatin for calpains by overexpression of calpastatin in SMB cells. Levels of C2 in SMB cells stably overexpressing human calpastatin were 64 Ϯ 15% lower (Ϯ S.D., n ϭ 4 independent experiments) than control transfected cells (p ϭ 0.0037) (Fig. 6a) .
We also evaluated whether C2 production could be modulated by ionophores that increase intracellular Ca 2ϩ with concomitant generation of calpain activity (23) . While calpain inhibition abrogated C2 cleavage, treatment of SMB cells for 1 h with the Ca 2ϩ ionophore ionomycin had the opposite effect, stimulating calpain-mediated cleavage of PrP in the presence of 2 mM Ca 2ϩ resulting in a dose-dependent increase in C2 with corresponding reductions in full-length PrP (Fig. 6b) . Maximal stimulation of C2 cleavage occurred at 5 M ionomycin with an average ϳ7-fold increase in C2 levels compared with control (n ϭ 3 independent experiments). Similarly, treatment with the Ca 2ϩ ionophore A23187 at a concentration of 1 M resulted in a 3.5-fold increase of C2 (n ϭ 3 independent experiments) (data not shown). We also examined the steady-state levels of m-and -calpain in SMB, SMB-PS, N2A, and ScN2A cells but found no appreciable differences between prion-infected and uninfected cells (Fig. 6c) . following PK treatment of detergent cell extracts. SMB cells treated with various concentrations of MDL28170 were lysed after 4 days when confluent (passage 1) and subcultured for a second passage in the presence of the same concentration of MDL28170. Similar to the effects on C2 levels, treatment of SMB cells with MDL28170 resulted in a time-and dose-dependent reduction in the amount of PrP- (27) (28) (29) (30) (Fig. 7, a and  b) . To determine the effects of MDL28170 in a different cell type persistently infected with mouse-adapted scrapie prions, ScN2A cells (19) were cultured in the presence of 50 M MDL28170 for varying amounts of time. Accumulation of PrP-(27-30) was reduced following 4 days of treatment in the presence of MDL28170 (passage 1) and decreased to almost undetectable levels by passage 4 (Fig. 7c) .
Calpain Inhibition Prevents PrP Sc Accumulation and Results in Reduced Prion
Since MDL28170 is a reversible calpain inhibitor (24), we investigated whether PrP Sc production could be reinitiated once calpain activity was restored. Sustained treatment of SMB cells with 50 M MDL28170 for 5 passages resulted in levels of PrP Sc that were undetectable by immunoblotting. Whereas PrP-(27-30) was undetectable by immunoblotting for a further 4 passages following removal of the inhibitor and growth in MDL28170-free medium (P1-P4 in Fig. 7d) , traces of PrP- (27) (28) (29) (30) were detected at the fifth passage in MDL28170-free medium suggesting a re-emergence of PrP Sc production (Fig. 7d, P5) .
To determine the effects of calpain inhibition on prion replication we performed bioassays of SMB cells treated with MDL28170 and control-treated SMB cells passaged in parallel. After 7 passages (total 33 days) in the presence of 50 M MDL28170, PrP-(27-30) was undetectable in treated SMB cells by immunoblotting (Fig. 7e, inset) . Inoculation of CD-1 Swiss mice (n ϭ 12) with MDL28170-treated SMB cells resulted in a mean incubation time of 170 Ϯ 2 days (Ϯ S.E.), which was significantly longer (p Ͻ 0.0001) than the mean incubation time of 126 Ϯ 1.3 days in CD-1 mice (n ϭ 12) inoculated with SMB cells treated in parallel with vehicle alone (Fig. 7e) . The extended incubation times reflected reduced prion titers in MDL28170-treated SMB cells (25) .
DISCUSSION
To better understand the role of PrP cleavage in prion disease, we analyzed PrP C and PrP Sc cleavage events in brain extracts from prion-inoculated mice and prion-infected cells in culture. Consistent with previous studies (1, 26) , we determined that production of C2 results from endoproteolytic cleavage of PrP Sc by a cellular protease in vivo. We used a combination of pharmacological and genetic approaches to ascertain the nature of the cellular protease responsible for PrP Sc cleavage and to address the role of the C2 cleavage product in the conversion of PrP C to PrP Sc and prion pathogenesis. Our hypothesis that endoproteolytic cleavage of PrP Sc and prion propagation is a calpain-dependent process is based on several independent but consistent observations. We tested a panel of membrane-permeable protease inhibitors for their ability to hinder the production of C2 in SMB cells. While pharmacological inhibitors of calpains prevented the production of C2, inhibitors of lysosomal proteases, caspases and the proteasome had no effect on C2 production in SMB cells. To address the issue of specificity in our pharmacological studies we used various inhibitors known to specifically target different cellular proteolytic pathways to circumvent the potential for cross-inhibition of cellular proteases. Since most pharmacological inhibitors of calpain also act as weak cathepsin inhibitors, particularly of cathepsin L, we were concerned that the effects we observed might be because of cross inhibition of that system. The demonstration that C2 levels were unaffected by treatment with cathepsin inhibitor III, a selective inhibitor of cathepsins B, L, and S and papain, or the more specific, irreversible cathepsin L inhibitor III, argues that the reductions in C2 levels observed in MDL28170-, calpain inhibitor IV-, and calpeptin-treated SMB cells were the result of specific inhibition of the calpain system. Previous studies demonstrating that leupeptin and E-64d affected PrP Sc accumulation in ScN2a cells (27, 28) may be interpreted either in a hypothetical framework involving the control of PrP Sc levels by calpain-dependent and other cysteine protease systems or, we feel more likely, in the context of the known abilities of these broad spectrum cysteine protease inhibitors to inhibit calpains. Importantly, while calpain inhibitors prevented production of C2, treatment of SMB cells with ionophores that increase intracellular Ca 2ϩ with concomitant generation of calpain activity had the opposite effect, resulting in consistent and significant increases in C2 levels. Finally, to substantiate the observation that pharmacological inhibition of calpains prevented cleavage of PrP highly specific and is regarded as the gold standard for demonstrating calpain-dependent cleavage.
We also found that calpain inhibition prevented PrP Sc accumulation in SMB as well as ScN2A cells and that prion titers in SMB cells were reduced following calpain inhibition. The reappearance of PrP Sc in SMB cells following MDL28170 treatment indicated that, while MDL28170 effectively inhibited the calpain-mediated cleavage of PrP Sc , the effects of the inhibitor on PrP Sc production were reversible. The apparent absence of PrP Sc by immunoblotting in the MDL28170-treated SMB inoculum following treatment for 7 passages (Fig. 7e, inset) and the presence of scrapie prions at reduced titers reflect the relative sensitivities of these two assays for prion detection. The ability to reverse the effects of MDL28170 treatment and observe the re-emergence of PrP Sc in SMB cells demonstrated that this reduction in prion titer corresponded to levels of PrP Sc that were undetectable by immunoblotting but which were sufficient to reinitiate the production and accumulation of additional PrP Sc once calpain activity was restored. Our studies also demonstrated an inverse relationship between the production of the C1 and C2 cleavage products which depended on the state of prion infection in vivo and in SMB cells. As C2 production was eliminated and PrP Sc levels declined in calpain inhibitor-treated SMB cells, C1 levels increased to the levels observed in uninfected cells (Figs. 4 and 5) . We considered the possibility that calpain inhibitors indirectly activated the endoproteolytic processing of PrP C resulting in increased C1 production and accompanying down-regulation of C2. However, since C1 levels were also higher in SMB-PS cells cured of prion infection by pentosan sulfate than in infected SMB cells (Figs. 2b and 6a) and C1 levels decreased as C2 levels and PrP- (27) (28) (29) (30) increased during prion infection in vivo (Fig. 3) , we feel that the increased levels of C1 subsequent to treatment with calpain inhibitors more likely reflects a conformation-dependent shift from PrP Sc to predominantly PrP C processing as cells change their infected status following inhibition of the C2 cleavage event. Levels of full-length PrP also decreased in response to treatments with calpain inhibitors (Figs. 4 and 5) , again most likely reflecting the shift from PrP Sc /PrP C production in the infected state to only PrP C production in the uninfected state. Calpain inhibition by calpastatin gene transfection was not as efficient or potent as treatment with pharmacological calpain inhibitors. Correspondingly, as C2 was maximally inhibited in calpain inhibitor IV or MDL28170-treated cells and C1 levels increased to the levels observed in uninfected cells, C1 levels remained lower when C2 production was only partially inhibited in SMB cells stably overexpressing human calpastatin.
As suggested by others (1), conformation-dependent cleavage of PrP C to produce C1 may be a critical determinant in preventing the accumulation of the pathogenic C2 fragment resulting from PrP Sc cleavage at residue 89. Consistent with this notion, epitopes in the region between residues 90 and 120, including the 3F4 binding site, which overlaps the C1 cleavage site, were found to be accessible to antibodies in PrP C but largely cryptic in PrP- (27) (28) (29) (30) (29) . Whereas our studies suggest that the PrP Sc conformation may favor cleavage at residue 89 to generate C2, it remains to be determined whether PrP, or specifically PrP Sc , is a calpain substrate. Interestingly, conformational features surrounding cleavage sites in known calpain substrates, particularly when associated with repeated domain elements such as those found in proteins such as tubulin, tau, spectrin, and calpastatin, affect calpain substrate sensitivity (30 -33) . Cleavage of PrP to produce C2 occurs immediately distal to a tandem array of five octapeptide repeats, which are frequently expanded in inherited cases of CJD (Fig. 1) . Whether a change in calpain activity and/or calpain redistribution to different subcellular localizations occurs during prion infection also remains to be determined. Since Ca 2ϩ modulates calpain activity, the observation that scrapie infection induces abnormalities in Ca 2ϩ homeostasis (34) may be significant. Also relevant in this regard are the findings that treatment of human SH-SY5Y neuroblastoma cells with the neurotoxic PrP-(106 -126) peptide resulted in a rapid rise in intracellular calcium and a concomitant increase in calpain activity (35) . Interestingly, quinacrine, the most potent substituted tricyclic inhibitor of PrP Sc accumulation (36) , blocks Ca 2ϩ channels (37) raising the intriguing possibility that its mode of action may, at least in part, be related to reducing intracellular Ca 2ϩ resulting in lower calpain activity. PrP C to PrP Sc conversion is thought most likely to occur in lipid rafts or in an early endosomal compartment (27, 38) . Increases in intracellular free Ca 2ϩ and Ca 2ϩ binding to calpain promote translocation of calpains to the plasma membrane (39) and co-localization of m-calpain with detergent-insoluble lipid rafts has been demonstrated in human Jurkat T-cells (40) . An important unresolved issue is whether calpains adopt a membrane topology that allows direct access to PrP Sc on the cell surface or in the lumen of intracellular vesicles.
